ITGR vs LMAT

Key Takeaways

• ITGR and LMAT both operate in the medical device industry but serve fundamentally different roles — ITGR is a large-scale contract manufacturing partner to OEMs, while LMAT is a specialized vascular device innovator selling branded products directly to surgeons.
• LMAT has delivered superior trailing one-year returns (approximately +27% versus approximately -9% for ITGR), though both stocks have posted strong year-to-date gains above 27% in 2026.
• LMAT maintains significantly higher gross margins (above 70%) and carries a pristine balance sheet with over $340 million in cash, whereas ITGR operates with higher financial leverage and a leverage ratio of roughly 3.0 times adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization).
• ITGR trades at a considerably lower valuation multiple (P/E ratio near 25 versus LMAT's P/E near 38), reflecting the market's differing growth and risk assessments for each company.
• LMAT pays a quarterly dividend yielding approximately 0.87%; ITGR does not distribute a dividend, making income-oriented considerations a differentiator between the two.
• Both companies have demonstrated resilient demand in their respective end markets, but their risk profiles diverge meaningfully when considering debt levels, customer concentration, and margin structure.

Introduction

This stock comparison examines ITGR (Integer Holdings Corporation) and LMAT (LeMaitre Vascular, Inc.), two publicly traded medical device companies that occupy distinct positions within the healthcare sector. While both generate revenue from cardiovascular-related medical products, their business models, scale, and financial profiles differ considerably. Integer Holdings is a contract development and manufacturing organization (CDMO) serving large original equipment manufacturers (OEMs), whereas LeMaitre Vascular designs, manufactures, and markets its own branded portfolio of vascular devices and implants directly to surgeons. This comparison is relevant for investors evaluating relative performance, growth trajectories, margin profiles, and risk characteristics within the medical device space — particularly those weighing a large-cap manufacturing partner against a smaller, higher-margin specialty player.

ITGR Overview and Recent Performance

ITGR, headquartered in Plano, Texas, is one of the world's largest medical device contract development and manufacturing organizations, employing approximately 11,000 people worldwide. The company provides critical components and finished devices to OEM clients across cardio and vascular, cardiac rhythm management, neuromodulation, advanced surgical, and orthopedics markets. In recent months, ITGR stock has staged a notable recovery, trading near $100 after bouncing from a 52-week low of $62.00. Year-to-date through late July 2026, the stock has gained roughly 27%, though it remains well below its all-time high near $144 set in January 2025.

Integer's full-year 2025 financial results illustrated operational momentum: sales grew 8% to $1.854 billion, adjusted operating income rose 13% to $321 million, and adjusted EPS (Earnings Per Share) climbed 21% to $6.40. The company has been actively managing its capital structure, including a $1.0 billion convertible notes offering and strategic acquisitions such as Precision Coating and VSi Parylene. However, total debt stood at approximately $1.185 billion at year-end 2025, contributing to a leverage ratio of 3.0 times adjusted EBITDA. CEO Payman Khales has guided toward returning to above-market organic growth by 2027, citing a strong product development pipeline. Analysts currently rate ITGR a consensus "Buy" with a 12-month price target around $101.

LMAT Overview and Recent Performance

LMAT, based in Burlington, Massachusetts, is a specialized provider of vascular devices, implants, and human tissue cryopreservation services focused on the treatment of peripheral vascular disease. With roughly 655 employees, the company operates a lean, high-margin model centered on a portfolio of approximately twelve branded products — including grafts, shunts, and catheters — sold primarily to vascular surgeons. In recent weeks, LMAT shares have traded around $103, reflecting a year-to-date gain of approximately 28% and an impressive trailing one-year return of roughly 27%. The stock's 52-week range spans from $79.01 to $118.01.

LeMaitre's financial performance has been consistently strong. Full-year 2025 revenue reached approximately $249.6 million, representing 13.5% year-over-year growth, while diluted EPS grew 30% to $2.52. Gross margins have remained above 70%, supported by favorable pricing, manufacturing efficiencies, and a direct sales model. In Q1 2026, net income surged over 42% compared to the prior-year quarter, with gross margins reaching 72.7%. Chairman and CEO George LeMaitre has highlighted the international launch of the company's Artegraft product as a key growth catalyst. Unlike ITGR, LMAT carries essentially no net debt and held approximately $343 million in cash as of its most recent filings, while also paying a quarterly dividend of $0.20 per share — an annualized yield near 0.87%.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of the platform's most promising AI-powered trading bots, each designed to navigate current market conditions using sophisticated Financial Learning Models (FLMs). With hundreds of AI trading bots available — covering thousands of different tickers across every major sector — Tickeron highlights only those strategies that demonstrate the strongest alignment with prevailing market dynamics. These bots span diverse trading styles, from 5-minute and 15-minute high-frequency agents to 60-minute swing trading models, and have posted annualized returns reaching as high as 232% in certain sector-specific strategies, with win rates frequently exceeding 65% and profit factors above 2.0. Each bot operates with its own unique strategy, risk parameters, and ticker universe, allowing traders to match automated approaches to their individual objectives. Explore the full selection on the Trending AI Robots page to discover which AI-driven strategies are currently leading the market.

Head-to-Head Comparison

The most fundamental distinction between ITGR and LMAT lies in their business models. ITGR functions as a CDMO, meaning its revenue depends on the product cycles, outsourcing decisions, and R&D (Research and Development) pipelines of its OEM customers. This creates a degree of customer concentration risk but also provides scale advantages — ITGR generated over $1.85 billion in 2025 revenue compared to LMAT's roughly $250 million. LMAT, by contrast, owns its customer relationships directly through a specialized sales force calling on vascular surgeons, giving it greater pricing power and brand loyalty.

Margin profiles tell a revealing story: LMAT's gross margins above 70% dramatically exceed ITGR's manufacturing-heavy cost structure, translating into superior returns on capital. LMAT's return on tangible equity has remained above 20%, while ITGR has carried negative tangible equity due to goodwill and intangible assets from acquisitions. On valuation, the market assigns LMAT a P/E multiple near 38, roughly 50% higher than ITGR's multiple near 25, reflecting LMAT's higher margins, asset-light model, and net cash position versus ITGR's leveraged balance sheet.

Risk factors diverge significantly. ITGR carries $1.185 billion in total debt and operates under a 3.0x leverage ratio, creating sensitivity to interest rate movements and refinancing risk. LMAT's net cash position provides substantial financial flexibility and downside protection. Conversely, ITGR's diversified product lines and blue-chip OEM customer base offer a different type of resilience — the company is embedded in long-term medical device programs that are difficult to displace. In terms of recent momentum, both stocks have performed similarly year-to-date (each up approximately 27-28%), but LMAT's smoother, less volatile longer-term trajectory — a 5-year total return exceeding 217% — stands in contrast to ITGR's more cyclical pattern, which includes a 40% drawdown in 2025.

Tickeron AI Verdict

Based on observable factors including trend consistency, financial stability, margin quality, and relative positioning, Tickeron's AI-driven analytical framework would likely express a near-term preference for LMAT over ITGR. LMAT's combination of higher and more stable gross margins, a debt-free balance sheet with substantial cash reserves, consistent double-digit organic revenue growth, and a rising dividend signal a lower-volatility return profile that AI models tend to favor. The stock's ability to maintain its premium valuation while delivering strong earnings growth suggests sustained institutional conviction. That said, ITGR's significantly lower valuation multiple and ongoing operational turnaround under new leadership present a potentially attractive mean-reversion opportunity — one that a different category of AI trading bot, particularly those focused on value or cyclical rotation strategies, might find compelling. In probabilistic terms, LMAT currently exhibits the steadier fundamental and technical picture, while ITGR offers higher potential reward coupled with higher balance-sheet risk.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations